Cefprozil Anhydrous, (E)-

CHEMBL276568 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
389.4 g/mol
LogP
-1.4
Phase
4

The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.

الوزن الجزيئي

389,4000 g/mol

LogP

-1,40

TPSA

158,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1

InChI

InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1

Molecular Formula

C18H19N3O5S

HBD / HBA

4 / 7

الروابط القابلة للدوران

5

الذرات الثقيلة

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefprozil Anhydrous, (E)- is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL276568. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5281006. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.